NICE has published 4 new rapid guidelines on the active management of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.
The guideline on rheumatological autoimmune, inflammatory and metabolic bone disorders says that patients with COVID-19 should not suddenly stop taking their medication but should seek advice on which medicines to continue and which to temporarily stop.
If they feel unwell, patients should contact their rheumatology team about any rheumatological medicines issues or if their condition worsens contact NHS 111 for advice on COVID-19. Healthcare professionals should use NHS England’s COVID-19 clinical guide when deciding what treatments are appropriate.
© NICE 2020 COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders. Available from the NICE website by clicking here. All rights reserved. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication. This guidance is published under the NICE-UK open content licence. You can access this licence by clicking here. The information above was correct at the time of publishing. This information is approved for use in the UK only.
Click here to read the Pharmacy in Practice Disclaimer. Click here to read your responsibility in regard to using NICE guidelines.